Anavex Life Sciences Corp. · NASDAQ:AVXL

Anavex Life Sciences — Investor Presentation (2015)

32 slides from Anavex Life Sciences's investor presentation, Nov 6, 2015

  1. Slide 1: Corporate Presentation Fall 2015

    Slide 1: Corporate Presentation Fall 2015

    AVXL Corporate Presenta0on Christopher U. Missling, PhD President & CEO Fall 2015

  2. Slide 2: Safe Harbor

    Slide 2: Safe Harbor

    Safe Harbor This presenta,on contains forward-­‐looking statements made within the meaning of the Private Securi,es Li,ga,on Reform Act of 1995 by Anavex™ Life Sciences Corp. and its representa,ves. These statements can be iden,fied by introductory words such as ``expects,'' ``plans,'' ``intends,'' `

  3. Slide 3: Anavex Overview

    Slide 3: Anavex Overview

    Anavex™ Overview § Lead drug ANAVEX™ 2-­‐73 and ANAVEX™ PLUS are currently in a Phase 2a clinical trial for Alzheimer‘s disease (AD) • Topline data at November Oral late-­‐breaker CTAD 2015 – preliminary data presented at July AAIC 2015 encouraging • ANAVEX PLUS is a combina,on of our proprietary c

  4. Slide 4: Broad Pipeline In Alzheimer's, Oncology and Pain

    Slide 4: Broad Pipeline In Alzheimer's, Oncology and Pain

    Broad Pipeline In Alzheimer’s, Oncology and Pain PRECLINICAL PHASE 1 PHASE 2 PHASE 3 ANAVEX™ PLUS ALZHEIMER’S ANAVEX™ 2-73 ALZHEIMER’S EPILEPSY PARKINSON’S RARE DISEASES ANAVEX™ 3-71 (AF710B) ALZHEIMER’S PARKINSON’S ANAVEX™ 1-41 DEPRESSION STROKE PARKINSON’S ALZHEIMER’S ANAVEX™ 1079 CANCER (MELANOMA

  5. Slide 5: Recent 3rd Party Publications on Sigma-1R Pathway: Additional Indications

    Slide 5: Recent 3rd Party Publications on Sigma-1R Pathway: Additional Indications

    Recent 3rd Party Publica0ons on Sigma-­‐1R Pathway: Addi0onal Indica0ons § Calcium target over-­‐expression IP3 may be involved in causing Alzheimer’s disease, same target regulated through Sigma-­‐1 receptor − K. FoskeN, K. et al., The Journal of Neuroscience, 14 May 2014, 34(20):6910-­‐6923 § Si

  6. Slide 6: Sigma-1 Receptor is a Multi-Targeted Key Cellular Modulator

    Slide 6: Sigma-1 Receptor is a Multi-Targeted Key Cellular Modulator

    Sigma-­‐1 Receptor is a Mul0-­‐Targeted Key Cellular Modulator ANAVEX § Blocking NOS § Enabling neuroprotec,on § Reducing protein misfolding § Modula,ng Ca2+ § Reducing oxida,ve stress § Reducing mitochondrial dysfunc,on § Reducing inflamma,on Cauli et al., Neuroscience, Volume 190, 2011, Page

  7. Slide 7: Sigma-1 Receptor Demonstrates Broad Range of Modulatory Effects

    Slide 7: Sigma-1 Receptor Demonstrates Broad Range of Modulatory Effects

    Sigma-­‐1 Receptor Demonstrates Broad Range of Modulatory Effects Sig-­‐1R Sig-­‐1R Increases Decreases Sigma-­‐1 R poten0ally beneficial for Neurodegenera0ve Diseases? 7 Francardo,V. Neural Regen Res. 2014 Nov 1; 9(21): 1882–1883.doi: 10.4103/1673-­‐5374.145351

  8. Slide 8: ANAVEX 2-73 Potential as Platform Drug: Strong Pre-Clinical Epilepsy Data

    Slide 8: ANAVEX 2-73 Potential as Platform Drug: Strong Pre-Clinical Epilepsy Data

    ANAVEX™ 2-­‐73 Poten0al as Pla]orm Drug for other CNS Indica0on’s: Strong Pre-­‐Clinical Epilepsy Data Significant An,-­‐Convulsive Ac,on of ANAVEX2-­‐73 Long-­‐Las,ng Effect Shown in PTZ-­‐ Against both MES and PTZ-­‐Induced Convulsions Induced Convulsions *** *** *** *** 100 *** *** 100 90 90 80 MES

  9. Slide 9: Alzheimer's is the Largest and Fastest Growing Therapeutic Area

    Slide 9: Alzheimer's is the Largest and Fastest Growing Therapeutic Area

    Alzheimer’s is the Largest and Fastest Growing Therapeu0c Area § More effec0ve and poten0ally disease-­‐modifying treatments will create a mul0billion dollar product market opportunity* $80bn $67.1bn $70bn $60bn Market Assuming $20,000 per year Potential $40bn treatment cost $30bn Assuming $100,000

  10. Slide 10: Alzheimer's: Complicated Cause with Tragic Outcome

    Slide 10: Alzheimer's: Complicated Cause with Tragic Outcome

    Alzheimer‘s: Complicated Cause with Tragic Outcome ... Stages of Increased Alzheimer’s burden Loss of speech; locomo,on, Terminal consciousness; death Very Severe Full-­‐,me care needed; ins,tu,onalized Can no longer care for self; incon,nent, depressed Severe Can no longer manage personal affairs; a

  11. Slide 11: Alzheimer's Disease is Complicated

    Slide 11: Alzheimer's Disease is Complicated

    Alzheimer‘s Disease is Complicated ... § Removing amyloid beta (A-­‐beta) plaques in the brain might be too simplis0c to be completely effec0ve -­‐ Recent disappointments of bapineuzumab (Pfizer), solanezumab (Eli Lilly), crenezumab (Roche) and gantenerumab (Roche) § More likely: Free-­‐floa0ng par0c

  12. Slide 12: Sigma-1 R: 2nd Line of Defense Against Chronic Stress

    Slide 12: Sigma-1 R: 2nd Line of Defense Against Chronic Stress

    Sigma-­‐1 R: “2nd Line of Defense” Against Chronic Stress Monomer Chronically Distressed Cell: Healthy Cell: Misfolded Proteins Quick Removal Sigma-­‐1R Acer U0liza0on Helping / S0mula0ng Ca2+ dysfunc,on ANAVEX 2-73 Own Body to Aß plays Regain important role in hippocampal Func0onality – memory Mito

  13. Slide 13: ANAVEX 2-73 Reverses Cycle of Protein Misfolding

    Slide 13: ANAVEX 2-73 Reverses Cycle of Protein Misfolding

    ANAVEX™ 2-­‐73 Reverses Cycle of Protein Misfolding Our therapeu0c’s Poten0al Mode of Ac0on -­‐ mixed muscarinic / Sig-­‐1R agonist Ca2+ modula,on, reducing inflamma,on, mitochondrial dysfunc,on, and oxida,ve stress, while also reducing both A-­‐beta and Tau ANAVEX 2-73 ANAVEX 2-73 ANAVEX 2-73 Exposi

  14. Slide 14: ANAVEX 3-71 Significantly Decreases Hallmark Pathologies in 3xTg-AD Model

    Slide 14: ANAVEX 3-71 Significantly Decreases Hallmark Pathologies in 3xTg-AD Model

    ANAVEX™ 3-­‐71 Significantly Decreases Hallmark Pathologies in 3xTg-­‐Alzheimer’s Disease Model § 10 month-­‐old 3xTg-­‐AD and WT mice § administered p.o. (oral) with tap water or ANAVEX 3-­‐71 (10 mcg/kg/ day) for 2 months 14 Presented at AAIC 2014

  15. Slide 15: ANAVEX 2-73 Significantly Improves Memory in Transgenic AD Model

    Slide 15: ANAVEX 2-73 Significantly Improves Memory in Transgenic AD Model

    ANAVEX™ 2-­‐73 Significantly Improves Memory in Transgenic Alzheimer's Disease Model (Tg2576) P<0.01 § 10 month-­‐old Tg2576 and WT male mice administered p.o. (oral) with tap water or ANAVEX™ 2-­‐73 (3 mg/kg/day); Azer 2 months, tested for place learning in the water-­‐maze; N = 6-­‐12 per group 15

  16. Slide 16: FDA Guidelines for Adaptive Trial and Population PK Design

    Slide 16: FDA Guidelines for Adaptive Trial and Population PK Design

    FDA Guidelines for Adap0ve Trial and Popula0on PK Design ü Fewer pa,ents needed ü Shorter dura,on required ü More likely to demonstrate an effect of the drug (if one exists) ü More informa,ve on the treatment’s effects ü Broader and beNer dose-­‐response informa,on and subgroup effects Leads to mo

  17. Slide 17: ANAVEX 2-73 / ANAVEX PLUS Efficient Clinical Trial Execution Plan

    Slide 17: ANAVEX 2-73 / ANAVEX PLUS Efficient Clinical Trial Execution Plan

    ANAVEX™ 2-­‐73 / ANAVEX™ PLUS Efficient Clinical Trial Execu0on Plan ANAVEX™2-­‐73-­‐001 Study: • Phase 1 (oral) • Single Ascending Dose (SAD) Completed • Healthy subjects ANAVEX™2-­‐73-­‐002 Study: • Phase 2a (oral) • Mild-­‐to-­‐moderate AD pa,ents Preliminary Posi0ve Data • Adap,ve trial with Popul

  18. Slide 18: ANAVEX 2-73: Integrated Phase 2a with Adaptive Trial Design

    Slide 18: ANAVEX 2-73: Integrated Phase 2a with Adaptive Trial Design

    ANAVEX™ 2-­‐73: Integrated Phase 2a with Adap0ve Trial Design PHASE 2a STUDY ANAVEX™ 2-­‐73 Dose A-­‐E Mild-­‐to-­‐moderate ANAVEX™ 2-­‐73 Dose A-­‐E + Donepezil AD pa0ents Donepezil* No. of Pa0ents: § 32 mild-­‐to-­‐moderate AD pa,ents No. of Sites: § Up to 7 sites Alloca0on: § Randomized Dura0o

  19. Slide 19: EEG/ERP Measuring Cognitive P300 Signal

    Slide 19: EEG/ERP Measuring Cognitive P300 Signal

    EEG (Electroencephalogram) /ERP (Event-­‐Related Poten0al) Measuring Cogni0ve P300 Signal § Demonstrates sensi,vity to Alzheimer’s disease § Real-­‐,me physiological measure of cogni,ve processes § More proximal to disease pathology and pharmacological interven,on than psychometric measures Coyne

  20. Slide 20: P300 Amplitude Change Correlates with ADAS-Cog and MMSE

    Slide 20: P300 Amplitude Change Correlates with ADAS-Cog and MMSE

    P300 Amplitude Change Correlates with ADAS-­‐Cog and MMSE P300 Change* 40% Study parameters: 30% § 15 pa,ents with mild AD (MMSE Change in % 20% 10% 0% 19-­‐26) on donepezil -10% -20% -30% § 15 pa,ents on control (Vitamin E) 2 3 6 Baseli 15 1 ne Days Month Month Month Month s s s § Double blind 6

  21. Slide 21: ANAVEX 2-73 Increases P300 Amplitude Earlier and 4x Higher than Donepezil

    Slide 21: ANAVEX 2-73 Increases P300 Amplitude Earlier and 4x Higher than Donepezil

    ANAVEX™ 2-­‐73 Increases P300 Amplitude Earlier and 4x Higher than Donepezil* P300 Change* 50% 40% 30% Change in % 20% 10% 0% -10% -20% -30% Baseline 15 Days 1 Month 2 Months 3 Months 6 Months Donepezil 0% 4% 10% 16% 22% 34% Control 0% -1% -7% -12% -13% -18% ANAVEX2-73 0% 38% * Historical control: D

  22. Slide 22: Clear Beneficial Effect of ANAVEX 2-73 on the P300 EEG/ERP Wave

    Slide 22: Clear Beneficial Effect of ANAVEX 2-73 on the P300 EEG/ERP Wave

    Clear Beneficial Effect of ANAVEX™ 2-­‐73 on the P300 EEG/ERP Wave P300 Baseline Day 36 Healthy Control* *Cecchi et al, subm. Alzheimer's & DemenJa, 2015 § ANAVEX2-­‐73 changes the ERP wave to resemble more closely the shape of healthy controls § ANAVEX™2-­‐73 data is from 12 pa,ents at baseline and

  23. Slide 23: ANAVEX 2-73 Increases P300 Amplitude by 38%

    Slide 23: ANAVEX 2-73 Increases P300 Amplitude by 38%

    ANAVEX™ 2-­‐73 Increases P300 Amplitude by 38% P300 Amplitude 9.00 8.00 7.00 Amplitude (mV) 6.00 5.00 4.00 3.00 2.00 1.00 0.00 Baseline Day 36 Healthy Ctrl* *Cecchi et al, subm. Alzheimer's & DemenJa, 2015 § ANAVEX™2-­‐73 increases the P300 amplitude by 38% from baseline § ANAVEX™2-­‐73 improves t

  24. Slide 24: ANAVEX 2-73 Improves both Accuracy and Reaction Time in ERP Test

    Slide 24: ANAVEX 2-73 Improves both Accuracy and Reaction Time in ERP Test

    ANAVEX™ 2-­‐73 Improves both Accuracy and Reac0on Time in the Target Detec0on Task of the ERP Test *Cecchi et al, subm. Alzheimer's & DemenJa, 2015 24 Presented at AAIC 2015

  25. Slide 25: ANAVEX 2-73 Completed Phase 1

    Slide 25: ANAVEX 2-73 Completed Phase 1

    ANAVEX™ 2-­‐73 Completed Phase 1 § Randomized, placebo-­‐controlled single ascending dose study § 22 healthy male volunteers § Strong safety profile -­‐No serious adverse event was reported, no study discon,nua,on -­‐Only at highest doses, observed adverse events included moderate and reversible d

  26. Slide 26: Comparable Companies

    Slide 26: Comparable Companies

    Comparable Companies Market Capitaliza0on($) Development Phase Ra0onale 1,500M Phase 2b 5-­‐HT6 antagonist Axovant (AXON) plus donepezil Avanir (AVNR) Acquired for 3,200M Marketed Sigma 1 Receptor Heptares M1 agonist, Acquired for 400M Phase 1b (Private) Alzheimer’s Prothena (PRTA) 2,000M Phase 1/2

  27. Slide 27: Financial Summary

    Slide 27: Financial Summary

    Financial Summary Symbol: AVXL Shares Outstanding: 31.1 million 52-­‐Week Stock Price Range: $0.60 -­‐ $7.96 Cash @ 9/15/2015: $13.1 million Cash Burn: ~$400K/month 27

  28. Slide 28: Strong Relevant Team Track Record

    Slide 28: Strong Relevant Team Track Record

    Strong Relevant Team Track Record Management and Directors Christopher U. Missling, PhD, MBA Tasos Zografidis, PhD Bernd Metzner, PhD Elliot Favus, MD Steffen Thomas, PhD Tom Skarpelos Scien0fic Advisory Board Abraham Fisher, PhD Jeffrey Cummings, MD Paul Aisen, MD Harald Hampel, MD, PhD Norman Relkin,

  29. Slide 29: 2015/16 Progress and Upcoming Milestones

    Slide 29: 2015/16 Progress and Upcoming Milestones

    2015/16 Progress and Upcoming Milestones þ Secure cGMP manufacturing for drug candidate trial supplies – 3Q 2014 þ Start Phase 2a study in 2014 Safety and exploratory efficacy þ Phase 1 full data in Q4 2014 þ Phase 2a – Report preliminary data in Q3 2015 þ Advance preclinical research with ANAVEX

  30. Slide 30: Anavex Overview

    Slide 30: Anavex Overview

    Anavex™ Overview § Lead drug ANAVEX™ 2-­‐73 and ANAVEX™ PLUS are currently in a Phase 2a clinical trial for Alzheimer‘s disease (AD) • Topline data at November Oral late-­‐breaker CTAD 2015 – preliminary data presented at July AAIC 2015 encouraging • ANAVEX PLUS is a combina,on of our proprietary c

  31. Slide 31: Today every 67 seconds someone develops Alzheimer's

    Slide 31: Today every 67 seconds someone develops Alzheimer's

    “… Today every 67 seconds someone develops Alzheimer’s” ̶ The Alzheimer’s AssociaJon Anavex™ is working on a poten,al solu,on. 31

  32. Slide 32: Contact Us

    Slide 32: Contact Us

    Contact Us Corporate Office: Anavex™ Life Sciences Corp. 51 West 52nd Street, 7th floor New York, NY 10019 (212) 332 4449 Shareholder & Media Rela0ons: Toll-­‐free: 1-­‐866-­‐505-­‐2895 Outside North America: + 1 (416) 489-­‐0092 Email: ir@anavex.com www.anavex.com AVXL 32 ANAVEX is a trademark of Anav

Source: Internet Archive copy of anavex.com

More decks from Anavex Life Sciences Corp.

All 35 Anavex Life Sciences decks